- Home
- SFST vs FBRX Comparison
SFST vs FBRX Comparison
Compare SFST & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SFST | FBRX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.6M | 487.2M |
| IPO Year | 2012 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SFST | FBRX |
|---|---|---|
| Price | $60.76 | $43.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $64.00 | ★ $67.00 |
| AVG Volume (30 Days) | 145.6K | ★ 616.9K |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | 61.30 |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $6,282,000.00 | $36,000.00 |
| Revenue This Year | $10.47 | N/A |
| Revenue Next Year | $12.19 | N/A |
| P/E Ratio | $51.16 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $38.48 | $9.12 |
| 52 Week High | $63.75 | $37.70 |
Technical Indicators
Market Signals| Indicator | SFST | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 85.89 |
| Support Level | $53.96 | $26.51 |
| Resistance Level | $61.81 | N/A |
| Average True Range (ATR) | 1.68 | 3.33 |
| MACD | -0.08 | 2.42 |
| Stochastic Oscillator | 50.43 | 93.80 |
Price Performance
Historical ComparisonAbout SFST Southern First Bancshares Inc.
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.